Atacicept FDA Approval Status
Last updated by Melisa Puckey, BPharm on Jan 31, 2024.
FDA Approved: No
Generic name: atacicept
Company: Vera Therapeutics, Inc.
Treatment for: Nephropathy
Atacicept is an investigational recombinant fusion protein used for IgA nephropathy to help reduce proteinuria and to stabilize eGFR.
- Participants treated with atacicept for 72 weeks showed consistent and sustained reductions in Gd-IgA1, hematuria, and UPCR, with stable eGFR over the duration of treatment.
- Data from 72-week trial with atacicept are consistent with a profile of true disease modification in IgAN.
IgA nephropathy (IgAN)
IgA nephropathy (IgAN), or Berger’s disease, is a rare, serious and progressive autoimmune disease of the kidney. IgAN is due to immune complexes that deposit in the kidney, causing inflammation and progressive damage. IgAN can lead to higher levels of protein in their urine (proteinuria) and may progress to end-stage renal disease (ESRD) or kidney failure, which has considerable morbidity and impact on patients’ lives.
About Atacicept
Atacicept is an investigational recombinant fusion protein that contains the soluble transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI) receptor that binds to the cytokines B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL). These cytokines are members of the tumor necrosis factor family that promote B-cell survival and autoantibody production associated with certain autoimmune diseases, including IgAN and lupus nephritis.
Atacicept works by targeting B cells and plasma cells to reduce autoantibodies.
Development timeline for atacicept
| Date | Article |
|---|---|
| Jan 25, 2024 | Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
